The FDA is seeking public feedback on plans to tailor [...]

NICE has recommended maralixibat for cholestatic pruritus caused by Alagille [...]

Polaryx Therapeutics is preparing to start its Phase 2 SOTERIA [...]

Andelyn Biosciences and Queen’s University have partnered to develop and [...]

Atsena Therapeutics has received EMA orphan designation for two gene [...]

VIVEbiotech has expanded its in vivo lentiviral vector portfolio to [...]

Chiesi Global Rare Diseases has launched the second edition of [...]

Allucent has appointed new therapeutic strategy leaders across key disease [...]

Cereno Scientific has reported initial long-term safety findings from a [...]

A new global initiative aims to address long-standing limitations in [...]